)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Almirall
Almirall (ALM) investor relations material
Almirall Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
9M 2026 net sales rose 8.3% YoY to €889.2m, led by European dermatology growth of 17.6%; EBITDA increased 22.7% to €221.7m, with a 24.9% margin.
Performance was described as aligned with FY26 guidance, which was reiterated.
Financial highlights
Total revenues increased 8.2% to €893.6m; gross profit rose 8.1% to €576.3m.
Q3 net sales were €286.5m, up 10.1% YoY; 9M EBITDA increased by approximately €40m versus 9M 2025.
SG&A was €365.7m, down 0.3% YoY; R&D was €107.1m, or 12.0% of sales.
Net income rose 36.3% to €53.3m; normalized net income increased 45.0% to €60.6m.
Outlook and guidance
FY26 guidance reiterated: net sales growth of 9%-12% and EBITDA of €270m-€290m; sales expected toward the mid-to-low end and EBITDA toward the upper end of ranges.
Ilumetri peak sales target remains above €300m; Ebglyss peak sales target remains above €450m.
First R&D readouts expected in Q4 2026; pipeline readouts continue through 2027 and early 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Almirall
- Net sales up 7.5% to €602.7M, EBITDA margin 25%, driven by dermatology and biologics.ALM
Q2 2026 - Net sales grew 2.2% YoY to €291M, driven by European dermatology and biologics strength.ALMQ1 2026
- 2025 net sales grew 12.4% and EBITDA 21%, driven by European dermatology and biologics.ALMQ4 2025
- Dermatology and biologics drove 12.8% net sales growth, with EBITDA up 27.1% YoY.ALMQ3 2025
- Net sales up 12.7% and EBITDA up 16.6% YoY, driven by strong dermatology and biologics growth.ALMQ2 2025
- Dermatology-driven sales and EBITDA growth with guidance reaffirmed for 2024.ALMQ3 2024
- Dermatology and biologics drove 6.7% sales and 3.2% EBITDA growth, supporting strong 2024 outlook.ALMQ2 2024
- Q1 net sales up 15% and EBITDA up 35%, driven by strong dermatology growth.ALMQ1 2025
- Double-digit sales and EBITDA growth in 2024, with strong outlook for 2025 and beyond.ALMQ4 2024
Next Almirall earnings date
Q4 202622 Feb, 2027
Almirall
Next Almirall earnings date
Q4 202622 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines. The company offers dermatological products that are used in the treatment of acne, psoriasis and other inflammatory skin diseases; aesthetic products that are used in the treatment of hair loss and to promote hair regrowth; and treating and preventing the excessive growth of sebaceous glands in adults, children and infants. Its products include Epiduo, Avage, Atralin Topical Solution, Acnomel Cream, Oustiderm Scalp Lotion, Tazorac Gel and Others.